|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...54555657585960616263646566» |
- | Trial completion: STCC: Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder (clinicaltrials.gov) - Mar 7, 2012
P1, N=22, Completed, Sponsor: Cadila Pharnmaceuticals
Recruiting --> Completed
- |||| cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Combination therapy, Metastases: A Study of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin in Advanced Non Small Cell Lung Cancer (clinicaltrials.gov) - Mar 7, 2012
P2, N=221, Completed, Sponsor: Cadila Pharnmaceuticals
Recruiting --> Completed Recruiting --> Completed
- |||||||||| New P3 trial: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India (clinicaltrials.gov) - Mar 6, 2012
P3, N=180, Active, not recruiting, Sponsor: Novartis
- Enrollment change: Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=60, Completed, Sponsor: University of Florida
Recruiting --> Completed N=100 --> 60
- ||||| New P4 trial: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Mar 5, 2012
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
- Trial completion: Antimicrobial Susceptibility Patterns of N. Gonorrhea Isolates in an Era of Quinolone Resistance (clinicaltrials.gov) - Mar 5, 2012
P=N/A, N=60, Completed, Sponsor: University of Florida
N=100 --> 60 Recruiting --> Completed
- | Enrollment change: Prevention of Persistence of Bacterial Vaginosis (clinicaltrials.gov) - Mar 4, 2012
P3, N=117, Terminated, Sponsor: Embil Pharmaceutical Co. Ltd
Recruiting --> Completed N=255 --> 117
- ibuprofen / Generic mfg., fosfomycin tromethamine / Generic mfg.
Enrollment open, HEOR: Immediate vs. Conditional Use of Antibiotics in Uncomplicated Urinary Tract Infection (UTI) - ICUTI (clinicaltrials.gov) - Mar 4, 2012
P4, N=494, Recruiting, Sponsor: Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
N=255 --> 117 Not yet recruiting --> Recruiting
- ||||||| Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi, PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer, Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion: A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months (clinicaltrials.gov) - Mar 4, 2012
P3, N=529, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||||| Twinrix (inactivated hepatitis A and recombinant hepatitis B) / GSK
Trial completion: Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine (clinicaltrials.gov) - Mar 1, 2012
P3, N=252, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- valacyclovir / Generic mfg.
Trial withdrawal: Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed Terminated --> Withdrawn
- valacyclovir / Generic mfg.
Enrollment change: Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=0, Withdrawn, Sponsor: University of Pittsburgh
Terminated --> Withdrawn N=1000 --> 0
- Enrollment open: BSARTA: Behavioral Science Aspects of Rapid Test Acceptance (clinicaltrials.gov) - Feb 28, 2012
P=N/A, N=1200, Recruiting, Sponsor: California State University, Long Beach
N=1000 --> 0 Not yet recruiting --> Recruiting
- | levofloxacin / Generic mfg., ceftaroline fosamil / Generic mfg.
Enrollment open: Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Feb 27, 2012
P4, N=16, Recruiting, Sponsor: Gary E. Stein, Pharm.D.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||||| Trial completion: Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12 (clinicaltrials.gov) - Feb 25, 2012
P2/3, N=1587, Completed, Sponsor: Novartis Vaccines
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Randomized Study of Not Giving Diphteria-tetanus-pertussis Vaccination With or After Measles Vaccination (clinicaltrials.gov) - Feb 24, 2012
P4, N=6534, Completed, Sponsor: Bandim Health Project
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || levofloxacin / Generic mfg.
New P3 trial: 5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection (clinicaltrials.gov) - Feb 21, 2012
P3, N=180, Completed, Sponsor: Second University of Naples
- meropenem / Generic mfg.
Enrollment closed: Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet (clinicaltrials.gov) - Feb 21, 2012
P=N/A, N=50, Active, not recruiting, Sponsor: Oslo University Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Trial completion: Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants (clinicaltrials.gov) - Feb 21, 2012
P2, N=1508, Completed, Sponsor: Novartis Vaccines
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- RotaTeq (Live attenuated pentavalent Rotavirus oral vaccine) / Merck (MSD)
Enrollment change: A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN) (clinicaltrials.gov) - Feb 20, 2012
P3, N=0, Withdrawn, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=336 --> 0
- | Thravixa (AVP-21D9) / Emergent Biosolutions
Trial completion, IO biomarker: Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9) (clinicaltrials.gov) - Feb 20, 2012
P1, N=50, Completed, Sponsor: Emergent BioSolutions
N=336 --> 0 Active, not recruiting --> Completed
- ||||| Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD)
Enrollment change, Pneumococcal vaccines: Revaccination With PNEUMOVAX(TM) 23 in Older Adults (V110-007) (clinicaltrials.gov) - Feb 16, 2012
P3, N=143, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed N=400 --> 143
- Enrollment change: EMR200059-504: Colposeptine for the Treatment of Bacterial Vaginosis (clinicaltrials.gov) - Feb 13, 2012
P4, N=133, Terminated, Sponsor: Merck KGaA
N=400 --> 143 N=87 --> 133
- rifampicin / Generic mfg.
Enrollment change: Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage (clinicaltrials.gov) - Feb 13, 2012
P4, N=175, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
N=87 --> 133 N=60 --> 175
- rifampicin / Generic mfg.
Trial completion: Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Anti-TB Drugs Induced Liver Damage (clinicaltrials.gov) - Feb 13, 2012
P4, N=175, Completed, Sponsor: All India Institute of Medical Sciences, New Delhi
N=60 --> 175 Recruiting --> Completed
- ||||| New P2 trial: Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis (clinicaltrials.gov) - Feb 12, 2012
P2, N=450, Active, not recruiting, Sponsor: NovaBay Pharmaceuticals, Inc.
- || New P3 trial, Adherence: Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (clinicaltrials.gov) - Feb 9, 2012
P3, N=1000, Recruiting, Sponsor: Centers for Disease Control and Prevention
- ||||||| Cayston (aztreonam lysine) / Gilead
Trial completion: Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection (clinicaltrials.gov) - Feb 9, 2012
P3, N=102, Completed, Sponsor: Gilead Sciences
Recruiting --> Completed Active, not recruiting --> Completed
- Clinical: Tuberculosis Recurrence Upon Treatment With Highly Active Antiretroviral Therapy (clinicaltrials.gov) - Feb 9, 2012
P=N/A, N=402, Active, not recruiting, Sponsor: Centre for the AIDS Programme of Research in South Africa
- |||||||||| ceftriaxone / Generic mfg., ceftaroline fosamil / Generic mfg.
New P2/3 trial: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) (clinicaltrials.gov) - Feb 8, 2012
P2/3, N=160, Recruiting, Sponsor: Cerexa, Inc.
- ||| New P1 trial: Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years (clinicaltrials.gov) - Feb 7, 2012
P1, N=420, Completed, Sponsor: Novartis Vaccines
- Trial completion: DoDoPi: Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho (clinicaltrials.gov) - Feb 7, 2012
P=N/A, N=1800, Completed, Sponsor: SolidarMed
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: TESEC-04: A Trial of the C-Tb Skin Test, When Given Intradermally to Adult Patients Recently Diagnosed With Active Tuberculosis (TB) (clinicaltrials.gov) - Feb 6, 2012
P2b, N=253, Completed, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed Recruiting --> Completed
- Trial completion: TESEC-03: A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG (clinicaltrials.gov) - Feb 6, 2012
P2a, N=151, Completed, Sponsor: Statens Serum Institut
Recruiting --> Completed Recruiting --> Completed
- Trial completion: THYB-03: A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31) (clinicaltrials.gov) - Feb 6, 2012
P1, N=39, Completed, Sponsor: Statens Serum Institut
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers (clinicaltrials.gov) - Feb 6, 2012
P1, N=38, Completed, Sponsor: Statens Serum Institut
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Trial completion: 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico (clinicaltrials.gov) - Feb 5, 2012
P3, N=324, Completed, Sponsor: Pfizer
Active, not recruiting --> Completed Recruiting --> Completed
- | Trial completion: Safety and Reactogenicity of a Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b (clinicaltrials.gov) - Feb 5, 2012
P1, N=40, Completed, Sponsor: Novartis Vaccines
Recruiting --> Completed Active, not recruiting --> Completed
- | Shanchol (oral cholera vaccine) / Sanofi
New P4 trial: Bridging Study for Killed Oral Cholera Vaccine in Ethiopia (clinicaltrials.gov) - Jan 31, 2012
P4, N=216, Completed, Sponsor: International Vaccine Institute
- | YHB1411-2 / Yuhan Corp
New P1 trial: Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of YHB1411-2 in Healthy Male Volunteers (clinicaltrials.gov) - Jan 31, 2012
P1, N=49, Completed, Sponsor: Yuhan Corporation
- | levofloxacin / Generic mfg., ceftaroline fosamil / Generic mfg.
New P4 trial: Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia (clinicaltrials.gov) - Jan 30, 2012
P4, N=16, Recruiting, Sponsor: Gary E. Stein, Pharm.D.
- Trial completion: Diagnostic Usefulness of Interferon Gamma Release Assay for Active Tuberculosis in Immunocompromised Patients (clinicaltrials.gov) - Jan 30, 2012
P=N/A, N=140, Completed, Sponsor: Yonsei University
Active, not recruiting --> Completed Recruiting --> Completed
- Cubicin (daptomycin) / Merck (MSD)
New P1 trial, Gram positive: Daptomycin in Pediatric Patients With Bacterial Meningitis (clinicaltrials.gov) - Jan 29, 2012
P1, N=5, Suspended, Sponsor: University Hospital Inselspital, Berne
- clarithromycin / Generic mfg.
New P4 trial: Drug Interaction Study Between Linezolid and Clarithromycin in Tuberculosis Patients (clinicaltrials.gov) - Jan 26, 2012
P4, N=7, Completed, Sponsor: University Medical Centre Groningen
- Trial completion: First Adult Safety Trial on Nasal Live Attenuated B. Pertussis Vaccine (clinicaltrials.gov) - Jan 26, 2012
P1, N=48, Completed, Sponsor: Institut National de la Sant
Recruiting --> Completed Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Enrollment change: Empiric Therapy of Mucopurulent Cervicitis (MPC) (clinicaltrials.gov) - Jan 25, 2012
P3, N=87, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=67 --> 87
- ||||| TOBI Podhaler (tobramycin inhalation powder) / Viatris
New P4 trial: Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis (clinicaltrials.gov) - Jan 25, 2012
P4, N=157, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
- |||||||||| Menactra (Meningococcal-groups A, C, Y and W-135 polysaccharide diphtheria toxoid conjugate vaccine) / Sanofi
New P3 trial: Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects (clinicaltrials.gov) - Jan 25, 2012
P3, N=200, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- ||||| Sivextro (tedizolid) / Merck (MSD), Nabriva Therap
New P2 trial, P2 data: A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study (clinicaltrials.gov) - Jan 25, 2012
P2, N=200, Completed, Sponsor: Trius Therapeutics, Inc.
- ||||||| Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK
Trial completion: Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine (clinicaltrials.gov) - Jan 25, 2012
P3, N=831, Completed, Sponsor: GlaxoSmithKline
N=67 --> 87 Active, not recruiting --> Completed